Skip to content

Study on the clinical efficacy of photodynamic therapy in the treatment of peri-implantitis: a single center, randomized controlled, prospective trial

Study on the clinical efficacy of photodynamic therapy in the treatment of peri-implantitis: a single center, randomized controlled, prospective trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018961
Enrollment
Unknown
Registered
2018-10-19
Start date
2018-02-01
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peri-implantitis

Interventions

Experimental Group:Mechanical debridement+photodynamic therapy

Sponsors

Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Male or female aged 18 to 80 years; (2) Patients are diagnosed as peri-implantitis; (3) Periodontal probing depth = 4 mm for at least 1 implant; (4) The plaque index = 2 points around the implant; (5) Bleeding happens after probing of the mucosa around the implant, and the sulcus bleeding index is = 2 points; (6) Periodontal attachment loss = 2.5 mm; (7) Pateients can understand and sign the informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with oral diseases/stomatological allergies on screening; (2) Antibiotics or non-steroidal anti-inflammatory drugs have been used within 3 months before diagnosis; (3) Patients who have been planted and repaired within one year; (4) Patients who have a history of alcohol abuse or drug abuse; (5) Long-term smokers; (6) Patients with implant loosening; (7) Patients whose ALT and / or AST are more than 1.5 times the upper limit of the normal value of our center, or the serum creatinine exceeds the upper limit of the normal value of our center; (8) Patients who have participated in other drug clinical trials within three months; (9) Pregnant or lactating women, or patients who have a pregnancy plan within a year; (10) Patients with a history of immunosuppressive diseases (such as history of HIV infection), a history of malignant tumors, a history of autoimmune diseases, a history of tuberculosis, a cardiovascular insufficiency, or a serious illness of other organ systems judged by the investigator; Any other circumstances that the investigators judge are not suitable for the trial.

Design outcomes

Primary

MeasureTime frame
Probing depth;Adverse events;

Secondary

MeasureTime frame
Plaque index around the implants;Sulcus bleeding index;Periodontal attachment loss;

Countries

China

Contacts

Public ContactZuomin Wang

Beijing Chaoyang Hospital, Capital Medical University, Beijing, China

wzuomin@sina.cn+86 13801263071

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026